Ian Walters, Portage Biotech CEO
Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline
A handful of Bristol Myers Squibb vets setting up a fledgling cancer drug developer have wrapped back-to-back stock deals to create a new oncology pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
